Board summary
Key figures
78,539
Registered population
68.4% aged 18–64
16.0%
Aged 65+
ICB 20.0% · England 17.9%
9.7%
Ethnic minority (non-White)
6.0% Asian · England 9.6%
15.6%
In IMD quintile 1
ICB 30.6% · England 21.0%
~11,451
Core20 residents (est.)
Resident basis; registered basis ~8,739 · see page 3
9,804
Hypertension register
+9.98% in 3 yrs · England +5.60%
856
SMI register
48.3% of Lancaster's
1,483
COPD register
Reviews -5.95% in 3 yrs
Forecast to 2030
11,837
Hypertension patients, 2030
+2,033 on today
70.0%
QRISK ≥20% on statins, 2030
+2.67pp over 3 yrs
4.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Annual chronic disease reviews fell against England.
From 2023 to 2025, heart failure reviews changed by -9.6% (England +8.7%), COPD by -6.0% (England +2.8%), and 64.7% asthma coverage leaves about 1,700.
Cervical screening and pre-school MMR2 uptake lag.
Cervical screening aged 25-49 is 57.6% (England 66.8%), while age-5 MMR coverage drops 7.5 pp from dose 1 (95.5%) to dose 2 (88.0%).
Register identification and diabetes HbA1c control grew.
From 2023 to 2025, non-frail diabetes HbA1c control rose +8.8% (England +4.4%), alongside register growth for learning disability (+19.1%), hypertension (+10.0%) and BP recording.
Population, age and ethnicity
Lancaster PCN's working-age share reaches 68.4%, exceeding borough, ICB and England benchmarks
Across 78,539 registered patients, 68.4% are aged 18-64, higher than Lancaster (61.2%), the ICB (60.4%) and England (62.7%), while 16.0% are aged 65+ (Lancaster 21.8%, ICB 20.0%, England 17.9%). Lancaster Medical Practice has 70.4% aged 18-64 and 14.6% aged 65+, whereas Queen Square Medical Practice has 60.4% aged 18-64 and 21.8% aged 65+. In Census resident data, White residents represent 90.3% (Lancaster 93.1%, ICB 87.8%, England 81.1%) and Asian residents 6.0% (Lancaster 3.6%, ICB 9.4%, England 9.6%), framing working-age service planning. Projected list growth to 2030 is +0.7% (Lancaster +0.5%, ICB +1.7%, England +2.3%) via an unverified model.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Lancaster local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Lancaster LA) | 1,840 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 82.8% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.3% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Lancaster LA) | 907 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Lancaster LA) | 10.4 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
PCN Core20 prevalence is 15.6%, with 7,166 estimated patients at Lancaster Medical Practice
Lancaster PCN's Core20 share is 15.6%, below Lancaster (21.5%), the ICB (30.6%) and England (21.0%), alongside an average IMD decile of 6.2. However, the weighted practice Core20 share is 11.1%, and resident deciles 1 to 2 counts (11,451) diverge from registered practice estimates (8,739). Deprivation volume sits heavily in Lancaster Medical Practice (11.3% share; 7,166 estimated patients), compared with Queen Square Medical Practice (10.3%; 1,573 estimated patients). Reconciling resident and registered lists is required before deploying targeted outreach.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
856
SMI register
1.05% recorded prevalence
325
Learning disability register
0.40% recorded prevalence
22
Care homes, 661 beds
In the PCN catchment
9.6%
Provide unpaid care
Lancaster, Census 2021
The PCN records 856 patients on the severe mental illness register (1.1%, Lancaster 1.1%, ICB 1.2%, England 1.0%) and 325 on the learning disability register (0.4%, Lancaster 0.5%, ICB 0.6%, England 0.6%), alongside 22 catchment care homes with 661 beds.
Severe mental illness: physical health checks
In SMI physical health checks, 80.6% received blood pressure checks (England 83.4%) and 76.8% BMI checks (England 82.1%). Over 2023 to 2025, blood pressure checks rose +1.4 pp (England +4.4 pp) and BMI checks rose +2.9 pp (England +5.1 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
9,804
Hypertension register
+9.98%
Register growth, 3 yrs
Lancaster +8.94% · England +5.60%
+3.66pp
BP control, under 80
≤140/90 · +0.67pp aged 80+
+2,033
More patients by 2030
Forecast 11,837 (14.56%)
Hypertension case-finding and control
Hypertension recorded prevalence is 12.0% across 9,804 registered patients, below Lancaster (15.5%), England (15.2%) and NHS Lancashire and South Cumbria Integrated Care Board (17.2%). Over 2023 to 2025, prevalence rose +10.0% (England +5.6%). Recent blood pressure checks reached 87.3% (England 90.0%, Lancaster 86.8%), and patients treated to target reached 68.0% (England 70.3%, Lancaster 65.2%). For patients aged under 80, control to <= 140/90 mmHg is 65.0% (England 67.8%). Across practices, prevalence is 11.5% at Lancaster Medical Practice and 14.3% at Queen Square Medical Practice. Lower recorded prevalence and treatment-to-target rates than England highlight operational scope to tighten blood pressure control through structured recall audits.
Lipids and statins
Lipid-lowering therapy reaches 64.2% of patients with QRISK ≥ 20% (England 63.6%, ICB 61.4%) and 73.4% in CKD (England 70.3%). However, statin treatment for diabetes without CVD fell 5.5% over 2023 to 2025 to 68.1% (England +2.1%, reaching 73.2%). Trailing national statin prescribing in diabetes may indicate missed primary prevention, making targeted diabetic medication review.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 113,725 | £1.70 | £1.64 | £1.86 | £193,332 |
| Cardiovascular (all), 2025 | 156,374 | £3.53 | £3.38 | £3.33 | £552,000 |
Lipid-regulating drugs averaged £1.70 per item across 113,725 items (England £1.86, Lancaster £2.09, ICB £1.64). Across these items, the PCN spent £18,196 less than at England's unit cost, but £6,824 more than at the ICB unit cost. Unit costs sit below England, keeping expenditure lower while clinical review targets statin initiation.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−0.01%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+3.09%
Asthma prevalence, PCN 3-yr % change
While the COPD register rose +6.7% over 2023 to 2025 (to 1,483 patients, 1.8%) and asthma rose +3.1% (to 4,809 patients, 6.2%), annual reviews slipped. COPD 12-month reviews fell 6.0% to 75.0% (England +2.8%, 76.4%), and asthma reviews changed -0.01% to 64.7% (England +4.4%), leaving about 1,700 patients unreviewed. Furthermore, asthma management prescribing among ages 5-19 reached 1,784 per 1,000 (England 1,488). Expanding registers alongside falling reviews and elevated youth prescribing may reflect strained clinical review capacity.
Cancer register and children's immunisation
Cancer prevalence stands at 3.2% across 2,587 registered patients (England 3.8%). In Q1 2025/26 childhood immunisations, age-5 4-in-1 booster coverage is 83.5% (below the 95% target by 11.5 pp across 133 children). Additionally, age-5 MMR coverage shows a 7.5 pp difference between dose one (95.5%) and dose two (88.0%, below the 95% target by 7 pp). This pattern is consistent with pre-school recall drop-off.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
In 2022, 52.4% of cancers with a known stage (4,642 of 8,863) were diagnosed at stage 1 or 2 across NHS Lancashire and South Cumbria ICB (England 55.3%, national ambition 75.0%), with known-stage completeness at 74.6% (8,863 of 11,883). Closing that ICB gap would require about 2,010 extra early-stage cases. Locally, cervical screening coverage in women aged 25-49 is 57.6% (England 66.8%), varying from 54.8% at Lancaster Medical Practice to 68.4% at Queen Square Medical Practice. Prioritising recall at the lowest-coverage practice offers the most direct local opportunity to support early detection.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For University Hospitals of Morecambe Bay NHS Foundation Trust in Jul 2026 (provisional), cancer 62-day referral to treatment was 72.4% against the 85.0% standard (England 71.2%, ICB 73.6%). The trust achieved 78.4% on the 28-day faster diagnosis standard against the 75.0% standard (England 79.3%, ICB 78.4%). Patients waiting 6+ weeks across all diagnostic tests stood at 10.4% in Jul 2026 (England 23.1%). These hospital provider metrics reflect wider system performance rather than PCN-level delivery. Shorter diagnostic waits provide supportive context for referral pathways despite system 62-day operational pressures.
| Pathways within standard (%) | of Morecambe Bay | Blackpool | Lancashire | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 78.39 | 71.38 | 82.90 | 78.39 | 79.32 |
| 31-day treatment (96%) | 95.22 | 97.96 | 89.43 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 72.35 | 67.48 | 75.04 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | of Morecambe Bay | Blackpool | Lancashire | England |
|---|---|---|---|---|
| MRI | 4.04 | 21.80 | 2.41 | 21.40 |
| CT | 13.76 | 16.49 | 14.97 | 9.92 |
| Echocardiography | 10.55 | 7.57 | 13.85 | 28.48 |
| Colonoscopy | 0.60 | 13.08 | 0.00 | 30.83 |
| Gastroscopy | 1.45 | 12.47 | 0.00 | 29.02 |
| All 15 DM01 tests | 10.44 | 26.54 | 26.65 | 23.14 |
| Community services activity | Lancashire residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 126,445 | 193,720 |
| Referrals | 20,415 | 29,855 |
| Patients with a contact | 47,320 | 65,335 |
Community services (residents of Lancashire), Jun 2026 (provisional). In Jun 2026 (provisional), Lancashire residents had 293,090 community care activities, 126,445 contacts, 47,320 patients with contact and 20,415 referrals; adults aged 65+ had 56.9% of contacts (72,000). The ICB recorded 533,345 activities and 193,720 contacts. These provisional wider-system figures are not PCN performance. Older adult community contacts highlight system interfaces for cancer and chronic care.
Practice variation and patient experience
QOF achievement reaches 95.4% and 95.5%, but vaccination achievement varies by 15.2 pp
In 2025/26, overall QOF achievement reached 95.5% at Lancaster Medical Practice and 95.4% at Queen Square Medical Practice (England 92.5%). Clinical-domain achievement was 100.0% at Lancaster Medical Practice and 97.8% at Queen Square Medical Practice (England 97.1%). Vaccination and immunisation achievement spanned 15.2 pp, from 60.5% at Lancaster Medical Practice to 75.8% at Queen Square Medical Practice (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Lancaster Medical | 124 | 11.3 | 51.2% | 84.8% | 83.0% |
| Queen Square | 112 | 10.3 | 55.1% | 70.0% | 75.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
12 of 25 tracked measures trail England's three-year change despite strong diabetes control
Twelve of 25 tracked measures trailed England's three-year change from 2023 to 2025. Annual reviews and prevention drove the widest lags: heart failure reviews fell 9.6% (England +8.7%), COPD reviews fell 6.0% (England +2.8%), smoking cessation offers fell 7.6 pp to 91.3% (England +0.1 pp), and diabetes statin treatment without CVD fell 5.5% (England +2.1%). Conversely, diabetes HbA1c control without frailty rose 8.8% to 56.3% (England +4.4%), and the learning disability register grew 19.1% (England +5.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
COPD reviews
Smoking support (SMI)
Diabetes statin (no CVD)
Asthma reviews
Cervical screening
Diabetes HbA1c control
Hypertension BP reading
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Lancaster | Asset | PCN | Lancaster |
|---|---|---|---|---|---|
| Care homes (catchment) | 22 (661 beds) | n/a | Schools (catchment) | 62 | n/a |
| Children's centres | 5 | 10 | Places of worship | 72 | 117 |
| Libraries | 4 | 7 | Day centres (VCS) | 1 | 1 |
| Children and young people (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 2 |
| Primary schools (LA maintained) | 30 | 49 | Primary academies | 2 | 3 |
| Special schools | 2 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured respiratory and heart failure recall
Asthma review coverage is 64.7% of 4,809 patients (England 65.7%), leaving 1,697 (about 1,700) unreviewed; COPD reviews fell 6.0% to 75.0% and heart failure fell 9.6% to 77.7%. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Pre-school MMR2 and booster recall
In Q1 2025/26 across 133 age-5 children, MMR drops 7.5 pp from dose 1 (95.5%) to dose 2 (88.0%, 7 pp below 95%), and 4-in-1 is 83.5% (11.5 pp below 95%). Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Combined SMI and CVD prevention checks
Across 856 SMI patients, BP checks are 80.6% (England 83.4%) and BMI 76.8% (England 82.1%); from 2023 to 2025, smoking cessation offers fell 7.6 pp and diabetic statins fell 5.5%. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Core20 register reconciliation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Coordinated SMI physical checks (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Systematic blood pressure recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephone access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured respiratory and heart failure recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD register | Core20PLUS5 respiratory | PCN |
| Option 2 · Pre-school MMR2 and booster recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · Combined SMI and CVD prevention checks (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
